Cencora (NYSE: COR) — Perfil da empresa, notícias e dados financeiros
Cencora provides healthcare services, managing costs and enhancing patient care through technology and innovation.
Cencora
Cencora is a global pharmaceutical solutions company providing wholesale drug distribution, specialty logistics, and healthcare services. Formed through the merger of Amerisource Health Corporation and Bergen Brunswig Corporation in 2001 and formerly named AmerisourceBergen, the organization supplies brand-name, generic, and specialty pharmaceuticals, over-the-counter products, and home healthcare equipment to healthcare providers, community pharmacies, and hospital systems. Cencora also delivers global commercialization services, clinical trial logistics, cold-chain storage, and patient access support to biopharmaceutical manufacturers. Headquartered in Conshohocken, Pennsylvania, the business maintains commercial operations across North America, Europe, Latin America, and the Asia-Pacific region.
Resumo
Operações
Produtos e/ou serviços de Cencora
- Wholesale and Specialty Distribution: Direct distribution of brand-name, generic, and specialty pharmaceutical products, over-the-counter consumer healthcare goods, and medical supplies to healthcare providers, retail pharmacies, and health systems across global commercial healthcare networks.
- Logistics and Warehousing: Specialized third-party logistics, temperature-controlled cold chain storage, and global supply chain management ensuring safe handling, secure warehousing, and rapid distribution of sensitive biopharmaceuticals, vaccines, and cell therapies.
- Commercialization Support: Comprehensive commercialization services, strategic market access consulting, regulatory advisory, and product launch solutions helping global biotechnology and pharmaceutical manufacturers navigate complex reimbursement, pricing, and market entry requirements worldwide.
- Patient Access and Support: Specialized patient assistance programs, hub services, benefit verification, co-pay assistance, and adherence support designed to minimize financial and administrative barriers, helping patients access and remain on prescribed specialty treatments.
- Pharmacy Solutions: Management tools, practice optimization software, inventory analytics, and group purchasing programs designed to help independent community pharmacies, retail pharmacy chains, and health-system pharmacies streamline operations and manage ongoing profitability.
- Clinical Development Support: Specialized clinical trial logistics, comparator sourcing, central laboratory logistics, and drug development support services designed to streamline early-phase clinical research and lower go-to-market risks for biopharmaceutical companies.
equipe executiva do Cencora
- Robert P. MauchPresident, CEO & Director
- Elizabeth S. CampbellExecutive VP & Chief Legal Officer
- James F. Cleary Jr.Advisor
- Silvana BattagliaAdvisor
- Eva C. BorattoExecutive VP & CFO
- Lazarus KrikorianSenior VP, Chief Accounting Officer & Corporate Controller
- Pawan Singh VermaExecutive VP and Chief Data & Information Officer
- Bennett S. MurphySenior VP Of Investor Relations & Enterprise Productivity and Treasury
- Samantha L. HammockExecutive VP & Chief Human Resources Officer
- Richard TremonteEVP and President of U.S. Pharmaceuticals & Animal Health
Histórico de dividendos
Dividendos por ação pagos pela Cencora, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026 | — | — | — | $2.4000 |
| FY2025 | — | — | — | $2.2000 |
| FY2024 | — | — | — | $2.0400 |
| FY2023 | — | — | — | $1.9400 |
| FY2022 | — | — | — | $1.8400 |
Principais indicadores financeiros
Resultados divulgados pela Cencora, em USD.
- Cap. de mercado
- 62,1 bi
- Receita (TTM)
- 332,8 bi
- P/L
- 24.2
- LPA (diluído, TTM)
- 13.5
- Dividend yield
- 0.7%
- Margem de lucro
- 0.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 321,3 bi | 3,6 bi | 1,6 bi | |
| 294 bi | 3 bi | 1,5 bi | |
| 262,2 bi | 2,4 bi | 1,7 bi | |
| 238,6 bi | 2,8 bi | 1,7 bi |